The collaboration combines Abbott′s glucose sensing technology with Omada Health's proprietary digital coaching platform to provide personalized care.
The contract will cover eligible members who are living with Type 1 or Type 2 diabetes, covering 5.3 million federal employees, retirees and their families.
The partnership will provide personalized diabetes support with the protection of life insurance and the potential to earn up to 25% in premium savings.
The device uses thermographic monitoring of a patient's feet to identify early onset of diabetic foot ulcers, which can lead to limb loss if not detected early.
This year, it is expected to exceed $742M, growing at an average CAGR of 50% annually.